This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Glycotest
Visit WebsitePortfolio company
United States
Sector: Medical Devices & Diagnostics
A liver disease diagnostics company commercialising new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis.
Exclusive, world-wide rights to over 50 patent-protected serum glycoprotein biomarkers that exploit novel sugar-based disease signals.
Tests revolutionise care and treatment for the at-risk, chronic liver disease population.
Product:
HCC Biomarker Panel
For early-stage primary liver cancer (hepatocellular carcinoma)
Subsidiaries
Portfolio
- ProAxsis
- Glycotest
- Cetromed
- PDS Biotechnology
- Vortex Biosciences
- Wanda Health
- Q-Bot
- Sofant Technologies
- PointGrab
- SageTech Medical
- Dname-iT
- Oncocidia
- Ventive
- DeepTech Recycling
- G-Tech Medical
- FOx Biosystems
- EpiBone
- Cytovale
- Longevity Biotech
- QuantalX Neuroscience
- Insight Photonics
- Nanotech Industrial Solutions
- Martlet Capital